Skip to content
stoqly

Xylem

XYL NYSE Industrial Machinery & Supplies & Components Financials FY2016–FY2025

Xylem's revenue rose 5.5% to $9.0 billion in fiscal 2025. Its operating margin was 13.5%, up from 11.8% a year earlier. Free cash flow was $910 million, down 3.4%. It paid out $406 million in dividends and buybacks, 45% of free cash flow. The diluted share count rose 0.2%.

Last close · Oct 23, 2026

$108.74

0.5%
Value it Compare
Revenue Total sales reported in the income statement.
$9.0B
5.5% vs prior year
Operating margin Operating income as a share of revenue.
13.5%
1.8 pts
Net income Profit after all expenses, interest and tax.
$957M
7.5%
Free cash flow Cash from operations minus capital spending.
$910M
3.4%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
8.1%
1.0 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$25.7B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
25.9x
On $4.20 EPS (TTM)

What Xylem does

No business description yet.

Legal name
Xylem Inc.
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001524472-26-000012
0001524472

Revenue and margins

Xylem had $9.0B of revenue in fiscal 2025, up 5.5% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 11.7% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $910M in fiscal 2025, 10.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Xylem returned $406M to shareholders in fiscal 2025, 45% of free cash flow. The diluted share count rose 0.2%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Xylem yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$1.1B and divides by 244.0M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 25.9x · peers 24.8x · sector 26.0x.

Balance sheet

Cash, debt and the ratios that show how comfortably Xylem can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $1.3B$944M$1.0B$1.1B$1.5B
Debt incl. finance leases $2.4B$1.9B$2.4B$2.2B$2.6B
Net debt / EBITDA 1.3x1.1x1.2x0.7x0.6x
Debt / equity 0.8x0.6x0.2x0.2x0.2x
Interest coverage 7.7x12.4x13.3x22.9x42.2x
Current ratio 2.3x1.9x1.8x1.8x1.6x
Quick ratio 1.8x1.4x1.3x1.3x1.3x
Total assets $8.3B$8.0B$16.1B$16.5B$17.6B
Total liabilities $5.1B$4.4B$5.9B$5.6B$5.9B
Shareholders' equity $3.2B$3.5B$10.2B$10.6B$11.5B
Net debt (− = net cash) $1.1B$961M$1.4B$1.1B$1.1B

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.1M

1 insider

Sold, 12 months

$2.3M

3 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
May 7, 2026 Geri-Michelle McShaneSVP, CAO Sold 4,269 $117.46 $0.5M Form 4
May 4, 2026 Jerome A PeribereDirector Bought 1,210 $116.61 $0.1M Form 4
Nov 4, 2025 Victoria D HarkerDirector Sold 1,700 $148.14 $0.3M Form 4
Oct 30, 2025 Claudia S ToussaintEVP, Cpso Sold 10,421 $152.64 $1.6M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✕ ✓
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✓ ✕
Current ratio rose ✕ ✕ ✕
Share count didn't rise ✕ ✕ ✕
Gross margin rose ✕ ✓ ✓
Revenue rose relative to assets ✓ ✕ ✓
F-score 6 / 95 / 96 / 9
Accruals ratio −1.9%−2.3%−1.7%
Altman Z'' 3.283.723.87

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Xylem XYL $25.7B 5.5% 13.5% 10.1% 8.1% 25.9x 6
Dover DOV $26.9B 4.5% 17.0% 13.8% 12.0% 23.2x 5 Compare →
Ingersoll Rand IR $28.8B 5.8% 15.0% 16.0% 6.5% 30.2x 5 Compare →
Hubbell HUBB $23.9B 3.8% 20.7% 15.0% 18.7% 26.5x 7 Compare →
Otis Worldwide OTIS $28.8B 1.2% 14.8% 10.0% 116.6% 19.3x 5 Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $3.8B $4.7B $5.2B $5.2B $4.9B $5.2B $5.5B $7.4B $8.6B $9.0B
Gross profit $1.5B $1.8B $2.0B $2.0B $1.8B $2.0B $2.1B $2.7B $3.2B $3.5B
Research and development $110M $181M $189M $191M $187M $204M $206M $232M $230M $226M
Operating income $408M $552M $654M $486M $367M $585M $622M $652M $1.0B $1.2B
Interest expense $70.0M $82.0M $82.0M $67.0M $77.0M $76.0M $50.0M $49.0M $44.0M $29.0M
Pretax income $340M $466M $585M $416M $285M $511M $440M $635M $1.1B $1.2B
Income tax $80.0M $136M $36.0M $15.0M $31.0M $84.0M $85.0M $26.0M $197M $231M
Net income $260M $331M $549M $401M $254M $427M $355M $609M $890M $957M
Diluted EPS $1.45 $1.83 $3.03 $2.21 $1.40 $2.35 $1.96 $2.79 $3.65 $3.92
Diluted shares 0.18B 0.18B 0.18B 0.18B 0.18B 0.18B 0.18B 0.22B 0.24B 0.24B
Cash flow
Cash from operations $497M $686M $586M $839M $824M $538M $596M $837M $1.3B $1.2B
Capital expenditure $124M $170M $237M $226M $183M $208M $208M $271M $321M $331M
Free cash flow $373M $516M $349M $613M $641M $330M $388M $566M $942M $910M
Depreciation and amortization $151M $234M $261M $257M $251M $245M $236M $436M $562M $575M
Stock-based compensation $18.0M $21.0M $30.0M $29.0M $26.0M $33.0M $37.0M $60.0M $56.0M $53.0M
Acquisitions $1.8B $33.0M $433M $18.0M $0.0M $0.0M $0.0M $476M $193M $163M
Share buybacks $4.0M $25.0M $59.0M $40.0M $61.0M $68.0M $52.0M $25.0M $20.0M $15.0M
Dividends paid $112M $130M $152M $174M $188M $203M $217M $299M $350M $391M
Dividends and buybacks $116M $155M $211M $214M $249M $271M $269M $324M $370M $406M
Balance sheet
Cash and short-term investments $308M $414M $296M $724M $1.9B $1.3B $944M $1.0B $1.1B $1.5B
Total debt $2.4B $2.2B $2.3B $2.3B $3.1B $2.4B $1.9B $2.3B $2.1B $2.5B
Finance lease liabilities $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $25.0M $86.0M $103M $125M
Current assets $1.8B $2.1B $2.1B $2.5B $3.5B $3.2B $3.0B $3.9B $4.1B $4.6B
Current liabilities $1.2B $1.1B $1.4B $1.5B $2.0B $1.4B $1.6B $2.2B $2.3B $2.9B
Inventory $522M $524M $595M $539M $558M $700M $799M $1.0B $996M $983M
Property and equipment, net $616M $643M $656M $658M $657M $644M $630M $1.2B $1.2B $1.2B
Total assets $6.5B $6.9B $7.2B $7.7B $8.8B $8.3B $8.0B $16.1B $16.5B $17.6B
Total liabilities $4.3B $4.3B $4.4B $4.7B $5.8B $5.1B $4.4B $5.9B $5.6B $5.9B
Shareholders' equity $2.2B $2.5B $2.8B $3.0B $3.0B $3.2B $3.5B $10.2B $10.6B $11.5B
Margins
Gross margin 38.8% 39.2% 38.9% 39.0% 37.5% 38.0% 37.7% 36.9% 37.5% 38.5%
Operating margin 10.8% 11.7% 12.6% 9.3% 7.5% 11.3% 11.3% 8.9% 11.8% 13.5%
EBITDA margin 14.8% 16.7% 17.6% 14.2% 12.7% 16.0% 15.5% 14.8% 18.4% 19.9%
Net margin 6.9% 7.0% 10.5% 7.6% 5.2% 8.2% 6.4% 8.3% 10.4% 10.6%
FCF margin 9.9% 11.0% 6.7% 11.7% 13.2% 6.4% 7.0% 7.7% 11.0% 10.1%
Returns
Return on capital 9.0% 9.1% 13.5% 10.0% 7.5% 11.5% 11.4% 7.8% 7.1% 8.1%
Return on capital employed 9.0% 10.0% 11.3% 8.1% 5.6% 8.6% 9.4% 6.4% 7.2% 8.5%
Return on equity 12.2% 14.1% 20.8% 14.0% 8.6% 13.8% 10.6% 8.9% 8.6% 8.7%
Return on assets 4.7% 5.0% 7.8% 5.4% 3.1% 5.0% 4.4% 5.1% 5.5% 5.6%
Growth
Revenue growth 3.2% 24.8% 10.6% 0.8% −7.1% 6.5% 6.3% 33.4% 16.3% 5.5%
Net income growth −23.5% 27.3% 65.9% −27.0% −36.7% 68.1% −16.9% 71.6% 46.1% 7.5%
EPS growth −22.5% 26.2% 65.6% −27.1% −36.7% 67.9% −16.6% 42.4% 30.8% 7.4%
FCF growth 7.5% 38.3% −32.4% 75.6% 4.6% −48.5% 17.6% 45.9% 66.4% −3.4%
Share count change −0.9% 0.5% 0.2% 0.0% −0.1% 0.2% −0.3% 20.6% 11.6% 0.2%
Financial health
Net debt / EBITDA 3.7x 2.3x 2.2x 2.1x 2.0x 1.3x 1.1x 1.2x 0.7x 0.6x
Debt / equity 1.1x 0.9x 0.8x 0.8x 1.0x 0.8x 0.6x 0.2x 0.2x 0.2x
Interest coverage 5.8x 6.7x 8.0x 7.3x 4.8x 7.7x 12.4x 13.3x 22.9x 42.2x
Current ratio 1.5x 1.9x 1.5x 1.6x 1.8x 2.3x 1.9x 1.8x 1.8x 1.6x
Quick ratio 1.1x 1.4x 1.1x 1.3x 1.5x 1.8x 1.4x 1.3x 1.3x 1.3x
Capital allocation
Capex / revenue 3.3% 3.6% 4.6% 4.3% 3.8% 4.0% 3.8% 3.7% 3.8% 3.7%
Stock comp / revenue 0.5% 0.5% 0.6% 0.6% 0.5% 0.6% 0.7% 0.8% 0.7% 0.6%
Payouts / FCF 31.1% 30.0% 60.5% 34.9% 38.9% 82.1% 69.3% 57.2% 39.3% 44.6%
Quality scores
Piotroski F-score 6.0 6.0 6.0 6.0 5.0 7.0 6.0 6.0 5.0 6.0
Altman Z'' 2.1 2.7 2.7 2.7 2.7 3.4 3.5 3.3 3.7 3.9
Accruals ratio −4.3% −5.3% −0.5% −5.9% −6.9% −1.3% −3.0% −1.9% −2.3% −1.7%

Source: SEC EDGAR XBRL filings (CIK 0001524472). Data updated October 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open